Regadenoson

Regadenoson: a new myocardial stress agent.

Vasodilator stress myocardial perfusion imaging (MPI) accounts for up to 50% of all stress MPI studies performed in the U.S. In 2008, the Food and Drug Administration approved regadenoson for stress testing in conjunction with MPI. Regadenoson, unlike adenosine, is a selective A(2A) agonist that is given as an intravenous bolus at a fixed dose, with less undesirable side effects including atrio...

Regadenoson — Overview of Applications in Cardiology

Coronary artery disease is a leading cause of morbidity and mortality in developed countries. According to a Center for Disease Control report, one out of four deaths is attributed to coronary artery disease. It costs the United States human lives, produc‐ tivity, and more than 100 billion dollars each year. Due to increased incidence in both men and women and all ethnicities, risk stratificati...

Regadenoson Cardiac Stress Myocardial Perfusion Scintigraphy

Safety and tolerability of regadenoson CMR

AIMS Knowledge of adverse events associated with regadenoson perfusion cardiac magnetic resonance (CMR) and patient tolerability has implications for patient safety and staff training. We sought to assess the safety and tolerability of regadenoson stress CMR. MATERIALS AND METHODS A group of 728 consecutive patients (median age 58, 44% female) and 25 normal volunteers (median age 21, 24% fema...

Regadenoson versus dipyridamole hyperemia for cardiac PET imaging.

OBJECTIVES The goal of this study was to compare regadenoson and dipyridamole hyperemia for quantitative myocardial perfusion imaging. BACKGROUND Regadenoson is commonly used for stress perfusion imaging. However, no study in nuclear cardiology has employed a paired design to compare quantitative hyperemic flow from regadenoson to more traditional agents such as dipyridamole. Additionally, th...